Cytomegalovirus Infections Archives

10 Biggest Novel Drug Approvals of 2021

Alzheimer's Disease, BNT162b2 (Pfizer and BioNTech), COVID-19 Vaccines, Cytomegalovirus Infections, Episodic Migraine, FDA, Lupus nephritis, New Drug Approvals, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer (NSCLC), Pfizer, Sickle Cell Disease, Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), Therapeutics, Weight management

BioSpace looks at the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease and Pfizer and BioNTech’s COVID-19 vaccine Comirnaty.

January 4, 2022/by BioSpace

FDA Advisory Committee Recommends Use Maribavir to Treat Post-Transplant Recipients with CMV Infection and Disease Refractory to Treatment With or Without Resistance

Adults, Advisory Panels, Antimicrobial Drugs Advisory Committee, Clinical Trials, Cytomegalovirus Infections, Organ Transplantation, R&D, Recommended For Approval, Takeda

The U.S. Food and Drug Administration Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of Takeda Pharmaceutical Company Limited’s maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease withgenotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

October 7, 2021/by Business Wire